---
title: "New China Life Insurance Strengthens Governance With Nomination and Remuneration Committee Rules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291255434.md"
description: "New China Life Insurance (HK:1336) has strengthened its corporate governance by establishing a Nomination and Remuneration Committee. Composed mainly of independent non-executive directors, the committee is responsible for setting selection criteria for directors and senior managers, reviewing board composition and diversity, and clarifying authority and responsibilities. This move aims to enhance oversight for stakeholders."
datetime: "2026-06-30T09:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291255434.md)
  - [en](https://longbridge.com/en/news/291255434.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291255434.md)
generator: "portal-rs"
---

# New China Life Insurance Strengthens Governance With Nomination and Remuneration Committee Rules

New China Life Insurance Co., Ltd. Class H ( (HK:1336) ) has shared an update.

New China Life Insurance Company Ltd. is a major life insurer in the People’s Republic of China, operating as a joint stock company with limited liability. The company focuses on life insurance and related financial services, and its shares are listed in Hong Kong under stock code 01336, reflecting its role in China’s broader insurance and financial markets.

The Board of New China Life Insurance has established a Nomination and Remuneration Committee composed mainly of independent non-executive directors, with defined qualifications and tenure aligned to Board terms. The detailed terms of reference clarify the committee’s authority, leadership structure, and responsibilities, including setting selection criteria for directors and senior managers and regularly reviewing the Board’s composition and diversity, strengthening corporate governance and oversight for stakeholders. 

The most recent analyst rating on (HK:1336) stock is a Sell  
 with a HK$33.00 price target.  
 To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock,  
 see the HK:1336 Stock Forecast page. 

**More about New China Life Insurance Co., Ltd. Class H**

New China Life Insurance Company Ltd. is a major life insurer in the People’s Republic of China, operating as a joint stock company with limited liability. The company focuses on life insurance and related financial services, and its shares are listed in Hong Kong under stock code 01336, reflecting its role in China’s broader insurance and financial markets.

The Board of New China Life Insurance has established a Nomination and Remuneration Committee composed mainly of independent non-executive directors, with defined qualifications and tenure aligned to Board terms. The detailed terms of reference clarify the committee’s authority, leadership structure, and responsibilities, including setting selection criteria for directors and senior managers and regularly reviewing the Board’s composition and diversity, strengthening corporate governance and oversight for stakeholders. 

**Average Trading Volume:** 9,578,294

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$191.3B

### Related Stocks

- [01336.HK](https://longbridge.com/en/quote/01336.HK.md)
- [601336.CN](https://longbridge.com/en/quote/601336.CN.md)

## Related News & Research

- [J.P. Morgan Sticks to Their Hold Rating for New China Life Insurance Co., Ltd. Class H (1336)](https://longbridge.com/en/news/294762808.md)
- [New China Life Insurance Forecasts 40%–60% Surge in First-Half 2026 Profit](https://longbridge.com/en/news/292476810.md)
- [Ping An Insurance (Group) Company of China: Net profit surged 36.1% YoY to RMB92.6bn; interim dividend up 3.2% to RMB0.98/share](https://longbridge.com/en/news/296469307.md)
- [AIA: Promising Demand from MCVs](https://longbridge.com/en/news/296437720.md)
- [Deutsche Bank AG Purchases 153,072 Shares of Manulife Financial Corp $MFC](https://longbridge.com/en/news/296453095.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**